The Psoriasis Biosimilars Market Size is valued at USD 8.5 billion in 2023 and is predicted to reach USD 19.3 billion by the year 2031 at a 10.9% CAGR during the forecast period for 2024-2031.
Biosimilars for psoriasis are economically viable substitutes for original biologics employed in the management of moderate to severe psoriasis. These medications closely mimic the original biologics, such as Humira, Enbrel, and Remicade, targeting immunological pathways to diminish inflammation and manage symptoms. Biosimilars provide accessibility to effective psoriasis treatments and undergo stringent testing for safety and efficacy.
The increasing number of people affected by psoriasis globally and the need for more reasonably priced treatment alternatives are the main factors driving the psoriasis biosimilars market's expansion. The affordability of biosimilars is another important factor. A larger patient population may now afford therapy thanks to biosimilars, which provide an inexpensive substitute for biologic medications as healthcare systems throughout the globe struggle with growing treatment costs. Further encouraging acceptance and adoption is the increasing knowledge of patients and medical professionals regarding the effectiveness of biosimilars.
The psoriasis biosimilar market is segmented based on drug class, route of administration, indication, and distribution channel. Based on drug class, the market is segmented into TNF-alpha inhibitors (infliximab, etanercept, adalimumab) and other biosimilars. As per the route of administration, the market is segmented into subcutaneous, intravenous. By indication, the market is segmented into plaque psoriasis, psoriatic arthritis, and other types. The distribution channel segment is categorised into hospital pharmacies, retail pharmacy chains and online pharmacies.
The plaque psoriasis category is expected to hold a major global market share. The need for effective and reasonably priced treatments has arisen from the chronic nature of plaque psoriasis and its detrimental effects on quality of life. Targeting particular pathways of the inflammatory process, biologics have shown promise in the treatment of moderate to severe plaque psoriasis. Yet, many patients are unable to afford the expensive therapies made from original biological processes, which presents a great opportunity for biosimilars. Biosimilars are very desirable to patients and healthcare professionals alike because they have profiles of efficacy and safety that are comparable to those of reference biologics but at significantly lower costs.
Retail pharmacies are typically found in very big businesses that span several cities or rural areas. This eliminates the need for the psoriasis sufferer to drive a great distance in order to obtain their biosimilar medication, which would be problematic for most of them as they depend on their meds frequently. Extended hours and easily accessible places are examples of convenience factors. Better prescription management results from this, and walk-in services are advantageous when managing a chronic ailment such as psoriasis, which frequently necessitates ongoing care.
The North American psoriasis biosimilar market is expected to capture a significant part of market revenue. North America possesses a formidable infrastructure for biotechnology research and development due to its vigorous pharmaceutical innovation. Moreover, the Asia Pacific region exhibited a significant market share. Contemporary technologies are employed in the advancement of biosimilars due to the region's significance in the biopharmaceutical sector. The prevalence in the population underscores the necessity for effective treatment, with biosimilars assuming a notably important role in the control of severe diseases.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 8.5 Bn |
|
Revenue Forecast In 2031 |
USD 19.3 Bn |
|
Growth Rate CAGR |
CAGR of 10.9% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Class, Route Of Administration, Indication, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Alvotech, Amgen, Amgen Inc., Biocon, Biogen, Biosimilar Collaborations Ireland Limited, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, Cordavis Ltd., Epirus Biopharmaceuticals, Fresenius Kabi, Glenmark Pharmaceuticals, Hanwha Chemical, Hetero, Innovent Biologics, Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics), LG Chem, Lupin, Mabpharm, Merck, Mylan, Nichi-Iko Pharmaceutical, Organon & Co., Pfizer, Ranbaxy Laboratories (now Sun Pharma), Samsung Bioepis, Sandoz, Shanghai CP Guojian Pharmaceutical, Sorrento Therapeutics (partner), Stada Arzneimittel AG, Sunshine Guojian Pharmaceutical, Synermore, Teva, Torrent Pharmaceuticals, YL Biologics, Zydus Cadila, Other prominent players. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Psoriasis Biosimilars Market Snapshot
Chapter 4. Global Psoriasis Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Psoriasis Biosimilars Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Psoriasis Biosimilars Industry Trends
Chapter 5. Psoriasis Biosimilars Market Segmentation 1: By Drug Class, Estimates & Trend Analysis
5.1. Market Share by Drug Class, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Class:
5.2.1. TNF-alpha Inhibitors
5.2.1.1. Infliximab
5.2.1.2. Etanercept
5.2.1.3. Adalimumab
5.2.2. Other Biosimilars
Chapter 6. Psoriasis Biosimilars Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Indications:
6.2.1. Plaque Psoriasis
6.2.2. Psoriatic Arthritis
6.2.3. Other Types
Chapter 7. Psoriasis Biosimilars Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administrations:
7.2.1. Subcutaneous
7.2.2. Intravenous
Chapter 8. Psoriasis Biosimilars Market Segmentation 4: By Sales Channel, Estimates & Trend Analysis
8.1. Market Share by Sales Channel, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Sales Channels:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacy Chains
8.2.3. Online Pharmacies
Chapter 9. Psoriasis Biosimilars Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Psoriasis Biosimilars Market, Regional Snapshot 2023 & 2031
9.2. North America
9.2.1. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.2.3. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.2.4. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.2.5. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.3. Europe
9.3.1. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.3.3. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.3.4. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.3.5. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.4. Asia Pacific
9.4.1. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.4.3. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.4.4. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
9.4.5. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.5. Latin America
9.5.1. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.5.3. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.5.4. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.5.5. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.6. Middle East & Africa
9.6.1. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.6.3. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.6.4. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.6.5. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Alvotech
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Offerings
10.2.1.3. Financial PerDrug Classance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Amgen Inc.
10.2.3. Biocon
10.2.4. Biogen
10.2.5. Biosimilar Collaborations Ireland Limited
10.2.6. Boeheringer Ingelheim
10.2.7. Celltrion
10.2.8. Cipla
10.2.9. Coherus Biosciences
10.2.10. Cordavis Ltd.
10.2.11. Epirus Biopharmaceuticals
10.2.12. Fresenius Kabi
10.2.13. Glenmark Pharmaceuticals
10.2.14. Hanwha Chemical
10.2.15. Hetero
10.2.16. Innovent Biologics
10.2.17. Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
10.2.18. LG Chem
10.2.19. Lupin
10.2.20. Mabpharm
10.2.21. Merck
10.2.22. Mylan
10.2.23. Nichi-Iko Pharmaceutical
10.2.24. Organon & Co.
10.2.25. Pfizer
10.2.26. Ranbaxy Laboratories (now Sun Pharma)
10.2.27. Samsung Bioepis
10.2.28. Sandoz
10.2.29. Shanghai CP Guojian Pharmaceutical
10.2.30. Sorrento Therapeutics (partner)
10.2.31. Stada Arzneimittel AG
10.2.32. Sunshine Guojian Pharmaceutical
10.2.33. Synermore
10.2.34. Teva
10.2.35. Torrent Pharmaceuticals
10.2.36. YL Biologics
10.2.37. Zydus Cadila
10.2.38. Other prominent players
Psoriasis Biosimilars Market By Drug Class-
Psoriasis Biosimilars Market By Route of Administration-
Psoriasis Biosimilars Market By Indication-
Psoriasis Biosimilars Market By Distribution Channel-
Psoriasis Biosimilars Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
